SG10201405039VA - Method of treating cancer - Google Patents
Method of treating cancerInfo
- Publication number
- SG10201405039VA SG10201405039VA SG10201405039VA SG10201405039VA SG10201405039VA SG 10201405039V A SG10201405039V A SG 10201405039VA SG 10201405039V A SG10201405039V A SG 10201405039VA SG 10201405039V A SG10201405039V A SG 10201405039VA SG 10201405039V A SG10201405039V A SG 10201405039VA
- Authority
- SG
- Singapore
- Prior art keywords
- treating cancer
- cancer
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23594709P | 2009-08-21 | 2009-08-21 | |
US30756910P | 2010-02-24 | 2010-02-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201405039VA true SG10201405039VA (en) | 2014-10-30 |
Family
ID=43607603
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201405039VA SG10201405039VA (en) | 2009-08-21 | 2010-08-20 | Method of treating cancer |
SG2012010658A SG178439A1 (en) | 2009-08-21 | 2010-08-20 | Method of treating cancer |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2012010658A SG178439A1 (en) | 2009-08-21 | 2010-08-20 | Method of treating cancer |
Country Status (26)
Country | Link |
---|---|
US (3) | US20120156200A1 (ja) |
EP (1) | EP2467140B1 (ja) |
JP (1) | JP5876827B2 (ja) |
KR (1) | KR101781658B1 (ja) |
CN (1) | CN102770140B (ja) |
AU (2) | AU2010284092A1 (ja) |
BR (1) | BR112012003653A2 (ja) |
CA (2) | CA2771699C (ja) |
CY (1) | CY1118486T1 (ja) |
DK (1) | DK2467140T3 (ja) |
EA (1) | EA027959B1 (ja) |
ES (1) | ES2589377T3 (ja) |
HR (1) | HRP20161110T1 (ja) |
HU (1) | HUE029098T2 (ja) |
IL (1) | IL218230B (ja) |
LT (1) | LT2467140T (ja) |
ME (1) | ME02492B (ja) |
MX (1) | MX367580B (ja) |
PL (1) | PL2467140T3 (ja) |
PT (1) | PT2467140T (ja) |
RS (1) | RS55074B1 (ja) |
SG (2) | SG10201405039VA (ja) |
SI (1) | SI2467140T1 (ja) |
SM (1) | SMT201600296B (ja) |
WO (1) | WO2011022633A2 (ja) |
ZA (1) | ZA201201110B (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011035540A1 (zh) | 2009-09-28 | 2011-03-31 | 齐鲁制药有限公司 | 作为酪氨酸激酶抑制剂的4-(取代苯胺基)喹唑啉衍生物 |
KR20140117644A (ko) * | 2012-01-31 | 2014-10-07 | 스미스클라인 비이참 (코르크) 리미티드 | 암을 치료하는 방법 |
GB201403820D0 (en) * | 2014-03-04 | 2014-04-16 | Isis Innovation | Assay |
CN104293958B (zh) * | 2014-10-16 | 2016-09-21 | 卫生部北京医院 | 一种预测强直性脊柱炎易感性的试剂盒和方法 |
BR112019012203A2 (pt) * | 2016-12-14 | 2019-11-12 | Beijing Genomics Inst At Shenzhen | marcadores genéticos humanos associados à resposta para tratamentos que têm como alvo a toxina b de clostridium difficile |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4582788A (en) | 1982-01-22 | 1986-04-15 | Cetus Corporation | HLA typing method and cDNA probes used therein |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5871918A (en) | 1996-06-20 | 1999-02-16 | The University Of North Carolina At Chapel Hill | Electrochemical detection of nucleic acid hybridization |
US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
JP2000508912A (ja) | 1996-04-19 | 2000-07-18 | スペクトラ バイオメディカル,インコーポレイテッド | 多型形態と複数の表現型との相関付け |
DE69716916T2 (de) | 1996-07-13 | 2003-07-03 | Glaxo Group Ltd., Greenford | Kondensierte heterozyklische verbindungen als protein kinase inhibitoren |
GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
AR031248A1 (es) | 2000-06-30 | 2003-09-17 | Glaxo Group Ltd | Compuestos de ditosilato de quinazolina, composicion farmaceutica, metodo de tratamiento y uso en terapia y proceso para la preparacion de dichos compuestos |
US20070281041A1 (en) * | 2004-03-02 | 2007-12-06 | Introgen Therapeutics, Inc. | Compositions and Methods Involving MDA-7 for the Treatment of Cancer |
US7794960B2 (en) * | 2004-06-04 | 2010-09-14 | Glaxosmithkline Llc | Predictive biomarkers in cancer therapy |
JP2007117085A (ja) | 2005-09-28 | 2007-05-17 | Genodive Pharma Kk | 塩酸チクロピジンの副作用である肝臓障害の発生危険率の検査方法 |
EP1988164A4 (en) | 2006-02-23 | 2009-04-22 | Univ Kanazawa Nat Univ Corp | METHOD FOR TESTING THE SENSITIVITY OF SOLIC CANCER AGAINST A TYROSINE KINASE INHIBITOR AND CORRESPONDING TEST REQUIREMENTS |
WO2008070448A2 (en) * | 2006-11-22 | 2008-06-12 | Board Of Regents, The University Of Texas System | Cancer-specific promoters |
US20080131887A1 (en) * | 2006-11-30 | 2008-06-05 | Stephan Dietrich A | Genetic Analysis Systems and Methods |
US20110286997A1 (en) * | 2007-03-13 | 2011-11-24 | Hakon Hakonarson | Genetic Alterations on Chromosome 16 and Methods of Use Thereof for the Diagnosis and Treatment of Type 1 Diabetes |
-
2010
- 2010-08-20 MX MX2012002161A patent/MX367580B/es active IP Right Grant
- 2010-08-20 EP EP10810654.3A patent/EP2467140B1/en active Active
- 2010-08-20 LT LTEP10810654.3T patent/LT2467140T/lt unknown
- 2010-08-20 ES ES10810654.3T patent/ES2589377T3/es active Active
- 2010-08-20 EA EA201270298A patent/EA027959B1/ru not_active IP Right Cessation
- 2010-08-20 PL PL10810654T patent/PL2467140T3/pl unknown
- 2010-08-20 KR KR1020127007152A patent/KR101781658B1/ko active IP Right Grant
- 2010-08-20 US US13/391,579 patent/US20120156200A1/en not_active Abandoned
- 2010-08-20 HU HUE10810654A patent/HUE029098T2/en unknown
- 2010-08-20 PT PT108106543T patent/PT2467140T/pt unknown
- 2010-08-20 RS RS20160681A patent/RS55074B1/sr unknown
- 2010-08-20 CA CA2771699A patent/CA2771699C/en active Active
- 2010-08-20 SI SI201031257A patent/SI2467140T1/sl unknown
- 2010-08-20 SG SG10201405039VA patent/SG10201405039VA/en unknown
- 2010-08-20 BR BR112012003653A patent/BR112012003653A2/pt not_active IP Right Cessation
- 2010-08-20 SG SG2012010658A patent/SG178439A1/en unknown
- 2010-08-20 ME MEP-2016-168A patent/ME02492B/me unknown
- 2010-08-20 CA CA3080511A patent/CA3080511C/en active Active
- 2010-08-20 AU AU2010284092A patent/AU2010284092A1/en not_active Abandoned
- 2010-08-20 CN CN201080047795.1A patent/CN102770140B/zh active Active
- 2010-08-20 JP JP2012525725A patent/JP5876827B2/ja active Active
- 2010-08-20 DK DK10810654.3T patent/DK2467140T3/en active
- 2010-08-20 WO PCT/US2010/046142 patent/WO2011022633A2/en active Application Filing
-
2012
- 2012-02-15 ZA ZA2012/01110A patent/ZA201201110B/en unknown
- 2012-02-20 IL IL218230A patent/IL218230B/en active IP Right Grant
-
2014
- 2014-06-17 AU AU2014203270A patent/AU2014203270B2/en not_active Revoked
-
2015
- 2015-02-27 US US14/634,052 patent/US9539257B2/en active Active
-
2016
- 2016-08-30 HR HRP20161110TT patent/HRP20161110T1/hr unknown
- 2016-09-01 CY CY20161100861T patent/CY1118486T1/el unknown
- 2016-09-01 SM SM201600296T patent/SMT201600296B/it unknown
- 2016-11-21 US US15/356,719 patent/US10004742B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276362A (en) | Cancer treatment methods | |
IL218575A0 (en) | Treatment of cancer | |
EP2643001A4 (en) | METHOD OF TREATING CANCER | |
IL223189A0 (en) | Methods of treatment of pancreatic cancer | |
PT2434891T (pt) | Métodos para tratamento de cancro e afeções não neoplásicas | |
HK1217763A1 (zh) | 用於治療疾病的方法 | |
HK1189272A1 (zh) | 治療癌症的方法 | |
EP2480579A4 (en) | METHODS OF TREATING INFLAMMATION | |
EP2640390A4 (en) | METHODS OF TREATING CANCER | |
IL215037A0 (en) | Treatment of pancreatic cancer | |
IL218230A0 (en) | Method of treating cancer | |
ZA201108493B (en) | Method of treating hair | |
EP2560648A4 (en) | METHOD OF TREATING PANCREATIC CANCER | |
EP2509599A4 (en) | METHOD FOR THE TREATMENT OF PANCREATIC CANCER | |
EP2593100A4 (en) | METHOD OF TREATING REFRACTORY CANCER | |
EP2560639A4 (en) | METHOD FOR THE TREATMENT OF PROSTATE CANCER | |
IL213919A0 (en) | Methods to treat cancer | |
GB0916686D0 (en) | Treatment of cancer | |
EP2560638A4 (en) | METHOD OF TREATING GASTRIC CANCER | |
EP2440238A4 (en) | Methods of Treatment | |
GB0921823D0 (en) | Method of treatment | |
GB0909807D0 (en) | Method of treatment | |
GB0904164D0 (en) | Method of treatment | |
GB0921757D0 (en) | Treatment of cancer | |
IL216629A0 (en) | Methods of treating inflammation |